CLAIMS

1. CuPTSM for use in the treatment ofa neurodegenerative disease in a subject in need thereof.

2. The use of claim 1, wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Parkinson's disease, Huntington's disease, and Alzheimer's disease.

3. The use of claims 1 or 2, wherein the neurodegenerative disease is ALS.

4. The use of claim 3, wherein the ALS is familial or sporadic.

5. The use of any of claims 1-4, wherein the subject in need thereof is treatment naïve.

6. The use of any of claims 1-4, wherein the subject in need thereof has received previous treatment for ALS.

7. The use of claim 1, wherein the therapeutically effective dose of CuPTSM is 0.01 mg/kg/day – 12 mg/kg/day.

8. The use of any of claims 1-7, wherein the subject in need thereof is human, and the human has a genetic mutation associated with ALS.

9. The use of claim 8, wherein the genetic mutation associated with ALS comprises a mutation in the *SOD1* gene.

10. The use of any of claims 1-9, wherein the CuPTSM is administered to the subject in combination with an additional ALS treatment therapy.

11. The use of claim 10, wherein the CuPTSM is administered at a dose that achieves a plasma Cmax of about 50-640 ng/mL in the subject.

12. A pharmaceutical composition comprising CuPTSM and a pharmaceutically acceptable excipient.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable excipient comprises cellulose and a surfactant.

14. The pharmaceutical composition of claim 13, wherein the cellulose is methylcellulose.

15. The pharmaceutical composition of claim 13, wherein the surfactant is a polysorbate.

16. The pharmaceutical composition of claim 15, wherein the polysorbate is TWEEN.

17. The pharmaceutical composition of claim 16, wherein the TWEEN is TWEEN-80.

18. A pharmaceutical composition comprising CuPTSM and a pharmaceutically acceptable excipient for use in the treatment of ALS in a subject in need thereof.

19. The pharmaceutical composition of claim 18, wherein the pharmaceutically acceptable excipient comprises cellulose and a surfactant.

20. The pharmaceutical composition of claim 19, wherein the cellulose is methylcellulose.

21. The pharmaceutical composition of claim 19, wherein the surfactant is a polysorbate.